Dr. Kunal Sur, PhD Co-Founder of Arete Bioscience Joins GlucoGuard's Scientific Advisory Board (SAB)
MWN-AI** Summary
Dr. Kunal Sur, PhD, co-founder of Arete Bioscience, has joined the Scientific Advisory Board (SAB) of GlucoGuard, a division of American Diversified Holdings Corporation (OTC: ADHC). His appointment reinforces Arete’s position as the engineering partner pivotal to GlucoGuard’s operations, particularly as the company progresses towards finalizing its FDA Break Through Device (BTD) application. This strategic move aims to streamline the pathway for regulatory approval and leverage Dr. Sur’s extensive experience in biomedical engineering and medical technology.
Based in Del Mar, California, GlucoGuard is innovating with its patent-pending nocturnal glucose monitoring and delivery system designed to prevent hypoglycemia in diabetic patients during sleep, addressing serious risks associated with low blood sugar levels. GlucoGuard's product features advanced technology that automatically monitors glucose levels and administers glucose as needed, utilizing artificial intelligence for accuracy and effectiveness.
Dr. Sur’s significant background in biotechnology, coupled with leadership roles in well-established firms such as Roche and GenMark Diagnostics, positions him uniquely to lead the engineering efforts for GlucoGuard’s devices. Alongside Dr. Stephen Weber, MD, and co-founder Zach Smith, Dr. Sur will not only guide product development but also explore potential acquisition opportunities for ADHC, indicating a broadening of the company’s strategic horizon.
The collaboration between Arete Bioscience and GlucoGuard promises to harness cutting-edge biomedical innovations for better diabetes management. With the diabetes market valued at approximately $28 billion in the U.S., the integration of GlucoGuard’s sophisticated glucose management solutions is well-timed to meet growing market demands. As GlucoGuard prepares for the next phase of development, the company remains focused on enhancing patient safety and technological advancement in diabetes care.
MWN-AI** Analysis
The recent announcement of Dr. Kunal Sur joining GlucoGuard's Scientific Advisory Board is a strategic development that could significantly influence the future trajectory of American Diversified Holdings (OTCID: ADHC) and its innovative glucose monitoring solution. Dr. Sur’s extensive experience in biomedical engineering is expected to expedite the FDA Breakthrough Device application process, indicating a promising timeline for market entry.
Investors should view this milestone as a positive signal. The incorporation of a seasoned professional like Dr. Sur, who has a proven track record with major firms such as Roche and GenMark Diagnostics, underscores GlucoGuard's commitment to pushing its technology from concept to production. The collaboration with Arete Bioscience reinforces the credibility of the engineering efforts behind the GlucoGuard device, which focuses on addressing critical issues related to nocturnal hypoglycemia in diabetes patients.
With the diabetes market projected to reach a valuation of $28 billion in the U.S. alone, there is a notable opportunity for growth within GlucoGuard. Their device, complemented by cutting-edge AI and continuous glucose monitoring technology in partnership with Dexcom, stands to capture significant market share as demand for innovative diabetes management solutions surges.
Investors considering ADHC should also look at the broader landscape of acquisitions and partnerships that Dr. Sur will oversee. These strategic moves can position GlucoGuard not only as a leader in nocturnal glucose monitoring but also expand its footprint in the competitive landscape of diabetes care technologies.
In essence, the convergence of expertise, technology, and market potential presents an attractive investment proposition. Stakeholders may find it prudent to monitor developments closely, as they could yield substantial returns as GlucoGuard moves towards FDA approval and commercialization.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Dr. Sur's Commitment Aligns Arete Bioscience as GlucoGuard's Ongoing Engineering Partner
Del Mar, California--(Newsfile Corp. - August 4, 2025) - The management team of GlucoGuard, a division of American Diversified Holdings (OTCID: ADHC) ("ADHC") announced today that Dr. Kunal Sur, PhD has agreed to join the company's Scientific Advisory Board. Dr. Kunal joins Dr. Stephen Weber, MD and GlucoGuards co-founder Zach Smith to guide GlucoGuard's next developmental phase.
Dr. Sur is the co-founder of Arete Bioscience and has been playing an integral role in the development of the prototype engineering for the GlucoGuard Device.
"Formalizing Dr. Sur's commitment to GlucoGuard solidifies our path forward as we finalize the FDA Break Through Device (BTD) application," commented ADHC. "The Arete Bioscience team, led by Kunal, is a major foundational component to streamlining the FDA approval process. We have assembled an all-star team as the final portion of the FDA (BTD) application is concluded."
In addition to the engineering work on the GlucoGuards prototype design, Dr. Sur will spear-head the review of other acquisition opportunities for ADHC, which is currently ongoing. Also, Dr. Sur will be coordinating future integration with Dexcom, GlucoGuards' Continuous Glucose Monitor "CGM" Development Partner.
Dr. Kunal Sur, PhD, is an experienced professional in the field of biomedical engineering, with a background in biotechnology and biochemical engineering, and is currently serving as the Managing Partner at Arete Biosciences, Inc. Prior to these roles, Kunal held various leadership positions at Roche, GenMark Diagnostics, Quidel and Hospira. Kunal earned their PhD and MS in Biomedical Engineering from Northwestern University, and a B. Tech in Biotechnology & Biochemical Engineering from the Indian Institute of Technology, Kharagpur.
ABOUT ARETE BIOSCIENCES, Inc.
End-to-End Health Tech Product Development
aretebiosciences.com
Arete BioSciences, Inc. ("Arete") is a contact service organization with expertise in the design and development of early-stage medical technologies. Arete maintains an extensive network of internal staff and collaborators with experience across device form factor exploration, rapid prototyping, and product visualization in the health space.
Arete BioSciences includes a team of scientists, strategic thinkers, problem solvers, engineers, and innovators passionate about creating a positive impact on global health. Projects include the design, development, and management of molecular diagnostic systems, molecular assays, start-ups, and build-ups of several companies, and have managed product development teams across four continents in seven countries.
ABOUT DR. STEPHEN WEBER, MD
Dr. Weber is currently an Assistant Professor at the Johns Hopkins School of Medicine. He previously served as a Medical Officer and Clinical Reviewer at The US Food and Drug Administration (FDA) and practiced medicine as an Orthopedic Surgeon for over 25 years.
ABOUT GLUCOGUARD
ADHC is a medical device company developing GlucoGuard, a patent-pending nocturnal glucose monitoring and delivery system for diabetic patients. The system helps prevent the dangerous effects of hypoglycemia "low blood sugar" during sleep, including the potentially fatal "Death in Bed" phenomenon. Collaborating with a leading U.S. research university, a prominent biomedical engineering firm, and a major CGM company, GlucoGuard is at the forefront of diabetes management technology.
GlucoGuard combines advanced engineering, artificial intelligence (AI), and mobile app-based monitoring to create an innovative solution for managing nocturnal Hypoglycemia. The GlucoGuard mouthpiece continuously monitors glucose levels during sleep and automatically administers glucose when hypoglycemic levels are detected. Sophisticated AI algorithms facilitate this process, ensuring effectiveness.
ABOUT THE DIABETES MARKET
The diabetes market is poised for substantial growth, with the U.S. market valued at $28 billion, underscoring the vast potential for GlucoGuard's adoption.
The Continuous Glucose Monitoring (CGM) sector, valued at $6.8 billion, further emphasizes the critical demand for advanced glucose management solutions.
For more information, visit: www.GlucoGuardSleep.com.
Contact: Phone: 817-525-0057
www.GlucoGuardSleep.com
www.UniversalWellnessAI.com
End-to-End Health Tech Product Development
aretebiosciences.com
John Cacchioli, CEO
American Diversified Holdings Corporation
Telephone: (212) 537-5900
Email: JC@American-Diversified.com
Social Media:
TWITTER: @ADHCManagement.
This Twitter page is the only official Twitter page for ADHC.
SAFE HARBOR FORWARD-LOOKING STATEMENTS: This press release may contain forward-looking statements that are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues related to our financial performance, expected revenue, contracts, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC) and on the OTC Disclosure & News Service (OTCDNS). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC and/or OTCDNS. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to the risk that we will not be able to find and secure construction contracts and the necessary assets that will enable us to become profitable. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC and/or OTCDNS filings. We have incurred and will continue to incur significant expenses in our development stage, noting that there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. New lines of business in the construction industry may expose us to additional legal and regulatory costs and unknown exposure(s), the impact of which cannot be predicted at this time. Words such as "estimate," "project," "predict," "will," "would," "should," "could," "may," "might," "anticipate," "plan," "intend," "believe," "expect," "aim," "goal," "target," "objective," "likely" or similar expressions that convey the prospective nature of events or outcomes generally indicate forward-looking statements. You should not place undue reliance on these forward-looking statements, which speak only as of this press release. Unless legally required, we undertake no obligation to update, modify or withdraw any forward-looking statements, because of new information, future events.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/261115
FAQ**
How does Dr. Kunal Sur's experience with Arete Bioscience enhance GlucoGuard's engineering capabilities and support the FDA Break Through Device application process for Amer Divrsfd Hldgs Corp ADHC?
What specific role will Dr. Sur play in identifying acquisition opportunities for Amer Divrsfd Hldgs Corp ADHC alongside his engineering commitments to the GlucoGuard project?
How will Dr. Sur’s collaboration with Dexcom as GlucoGuard's CGM partner influence the overall development trajectory of diabetic management solutions at Amer Divrsfd Hldgs Corp ADHC?
Could you elaborate on the expected timeline for the FDA approval process and how the collaboration with Dr. Sur and Arete Bioscience aligns with Amer Divrsfd Hldgs Corp ADHC's growth strategy?
**MWN-AI FAQ is based on asking OpenAI questions about American Diversified Holdings Corp (OTC: ADHC).
NASDAQ: ADHC
ADHC Trading
0.0% G/L:
$0.0006 Last:
834,933 Volume:
$0.0006 Open:
